InvestSMART

Acrux Limited (ASX: ACR) - Announcements

- Current share price for ACR : $0.010

ASX company news and announcements for Acrux Limited (ACR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Acrux Limited (ACR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Acrux Limited (ACR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Acrux Limited (ACR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$6 Half Year Accounts and Appendix 4D 24 Feb 2011 9:29AM $3.700 $0.010 fallen by 99.73%
$6 Appendix 4C - Quarterly Cash Flow Report 31 Jan 2011 4:20PM $3.550 $0.010 fallen by 99.72%
$6 2010 AGM Presentations 30 Nov 2010 2:00PM $3.380 $0.010 fallen by 99.70%
$6 FDA Approval for AXIRON 24 Nov 2010 2:10PM $3.360 $0.010 fallen by 99.70%
$6 Market Update 24 Nov 2010 2:10PM $3.360 $0.010 fallen by 99.70%
$6 Trading Halt 24 Nov 2010 9:28AM $3.360 $0.010 fallen by 99.70%
$6 Response to ASX Price Query 1 Nov 2010 8:58AM $3.070 $0.010 fallen by 99.67%
$6 Appendix 4C - Quarterly Cash Flow Report 29 Oct 2010 5:24PM $3.140 $0.010 fallen by 99.68%
$6 Appendix 4E and 30 June 2010 Financial Report 24 Aug 2010 9:43AM $2.010 $0.010 fallen by 99.50%
$6 Update on Acrux female health products 10 Aug 2010 10:56AM $1.990 $0.010 fallen by 99.50%
$6 Appendix 4C - Quarterly Cash Flow Report 30 Jul 2010 12:06PM $1.950 $0.010 fallen by 99.49%
$6 Settlement Agreement Transferring Luramist Assets to Acrux 11 May 2010 1:48PM $1.900 $0.010 fallen by 99.47%
$6 Appendix 4C - Quarterly Cash Flow Report 30 Apr 2010 4:45PM $1.910 $0.010 fallen by 99.48%
$6 New Drug Application for AXIRON accepted for review by FDA 15 Apr 2010 10:05AM $2.290 $0.010 fallen by 99.56%
$6 Acrux to regain rights to testosterone spray from Vivus 1 Apr 2010 10:23AM $2.320 $0.010 fallen by 99.57%
$6 Acrux and Eli Lilly sign global licensing deal for AXIRON 16 Mar 2010 10:14AM $2.430 $0.010 fallen by 99.59%
$6 Market Update - A New Era For Acrux 16 Mar 2010 9:48AM $2.430 $0.010 fallen by 99.59%
$6 Trading Halt 15 Mar 2010 10:40AM $2.380 $0.010 fallen by 99.58%
$6 Half Year Accounts and Appendix 4D 24 Feb 2010 9:57AM $2.480 $0.010 fallen by 99.60%
$6 Appendix 4C - Quarterly Cash Flow 29 Jan 2010 4:52PM $2.050 $0.010 fallen by 99.51%
$6 Acrux Submits New Drug Application for AXIRON to FDA 27 Jan 2010 9:39AM $2.020 $0.010 fallen by 99.50%
$6 Appendix 4C - Quarterly Cash Flow 30 Oct 2009 2:30PM $2.260 $0.010 fallen by 99.56%
$6 Acrux Announces Successful AXIRON Phase 3 Trial Results 29 Sep 2009 9:33AM $1.610 $0.010 fallen by 99.38%
$6 Acrux Signs Ellavie Distribution Agreement for Key European 24 Sep 2009 11:00AM $1.540 $0.010 fallen by 99.35%
$6 Acrux to proceed with AXIRON NDA following meeting with FDA 3 Sep 2009 10:17AM $1.350 $0.010 fallen by 99.26%

576 - 600 of 699 results

Page 24 of 28

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.